Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid Tamibarotene

British Journal of Haematology

Volumn 151, Issue 1, 2010, Pages 99-101

  Di Veroli, Ambra ^a   Ramadan, Safaa M ^a,b   Divona, Mariadomenica ^a   Cudillo, Laura ^a   Giannì, Laura ^a   Wieland, Scott ^c   Giannotti, Federica ^a   Mirabile, Milena ^d   Arcese, William ^a   Lo Coco, Francesco ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c CytRx Corporation   (United States)

^d NONE

Author keywords

acute promyelocytic leukaemia; ATO; molecular remission; synthetic all trans retinoic acid; Tamibarotene

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; METHOTREXATE; PREDNISONE; RETINOIC ACID; TAMIBAROTENE; ANTINEOPLASTIC AGENT; BENZOIC ACID DERIVATIVE; TETRALIN DERIVATIVE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CEREBROSPINAL FLUID; DRUG WITHDRAWAL; FEMALE; HLA SYSTEM; HUMAN; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT INTERVAL; SIDE EFFECT; TREMOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, PROMYELOCYTIC, ACUTE; RECURRENT DISEASE;

ADULT; ANTINEOPLASTIC AGENTS; BENZOATES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; RECURRENCE; TETRAHYDRONAPHTHALENES;

EID: 77956803066     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08308.x     Document Type: Letter

References (7)

1. Au, W.Y., Tam, S., Fong, B.M. Kwong, Y.L. (2008) Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood, 112, 3587 3590.
2. Avvisati, G., Lo-Coco, F., Diverio, D., Falda, M., Ferrara, F., Lazzarino, M., Russo, D., Petti, M.C. Mandelli, F. (1996) AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood, 88, 1390 1398.
3. Cortes-Franco, J., Coutre, S., Di Bona, E., Lo-Coco, F., Wetzler, M., Sanz, M., Wieland, S., Barber, J.R. Kantarjian, H.M. (2009) A phase II study of oral tamibarotene in acute promyelocytic leukemia (APL) patients (PTS) who have received prior therapy with all-trans retinoic acid and arsenic trioxide (STAR-1 trial). Blood (ASH Annual Meeting Abstracts), 114, 2050.
4. Ohnishi, K. (2007) PML-RARα inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. International Journal of Clinical Oncology, 12, 313 317.
5. Sanz, M.A., Lo-Coco, F., Martín, G., Avvisati, G., Rayón, C., Barbui, T., Díaz-Mediavilla, J., Fioritoni, G., González, J.D., Liso, V., Esteve, J., Ferrara, F., Bolufer, P., Bernasconi, C., Gonzalez, M., Rodeghiero, F., Colomer, D., Petti, M.C., Ribera, J.M. Mandelli, F. (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood, 96, 1247 1253.
6. Sanz, M.A., Grimwade, D., Tallman, M.S., Lowenberg, B., Fenaux, P., Estey, E.H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., Burnett, A.K. Lo-Coco, F. (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 113, 1875 1891.
7. Tobita, T., Takeshita, A., Kitamura, K., Ohnishi, K., Yanagi, M., Hiraoka, A., Karasuno, T., Takeuchi, M., Miyawaki, S., Ueda, R., Naoe, T. Ohno, R. (1997) Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood, 90, 967 973. (Pubitemid 27314129)